CartiHeal has developed the Agili-C™, a biocompatible, coral-based implant designed for osteochondral joint repair. This innovative solution allows surgeons to insert a cylindrical implant into the patient’s knee, significantly reducing pain while enabling the regeneration of damaged cartilage. Suitable for a wide patient population, including those with mild to moderate osteoarthritis, the Agili-C™ offers a one-step, off-the-shelf treatment option.

CartiHeal’s groundbreaking technology has received FDA breakthrough designation and approval, following clinical trials that demonstrated its effectiveness in improving joint function and patient outcomes.

In 2023, the company was acquired by Smith+Nephew for up to $330 million.